Neoantigens in Hematological Malignancies—Ultimate Targets for Immunotherapy?

by Malte Roerden, Malte Roerden, Annika Nelde, Annika Nelde, Juliane S. Walz, Juliane S. Walz, Juliane S. Walz
Published 2019-12-01

Antigen Targets for the Development of Immunotherapies in Leukemia

by Jens Bauer, Annika Nelde, Tatjana Bilich, Juliane S. Walz
Published 2019-03-01

HLA Evolutionary Divergence as a Prognostic Marker for AML Patients Undergoing Allogeneic Stem Cell Transplantation

by Malte Roerden, Annika Nelde, Jonas S. Heitmann, Reinhild Klein, Hans-Georg Rammensee, Wolfgang A. Bethge, Juliane S. Walz
Published 2020-07-01

Immunopeptidomics-Guided Warehouse Design for Peptide-Based Immunotherapy in Chronic Lymphocytic Leukemia

by Annika Nelde, Annika Nelde, Annika Nelde, Yacine Maringer, Yacine Maringer, Yacine Maringer, Tatjana Bilich, Tatjana Bilich, Tatjana Bilich, Helmut R. Salih, Helmut R. Salih, Malte Roerden, Malte Roerden, Malte Roerden, Jonas S. Heitmann, Jonas S. Heitmann, Ana Marcu, Jens Bauer, Jens Bauer, Marian C. Neidert, Claudio Denzlinger, Gerald Illerhaus, Walter Erich Aulitzky, Hans-Georg Rammensee, Hans-Georg Rammensee, Hans-Georg Rammensee, Juliane S. Walz, Juliane S. Walz, Juliane S. Walz, Juliane S. Walz
Published 2021-07-01

HLA ligandome analysis of primary chronic lymphocytic leukemia (CLL) cells under lenalidomide treatment confirms the suitability of lenalidomide for combination with T-cell-based i...

by Annika Nelde, Daniel J. Kowalewski, Linus Backert, Heiko Schuster, Jan-Ole Werner, Reinhild Klein, Oliver Kohlbacher, Lothar Kanz, Helmut R. Salih, Hans-Georg Rammensee, Stefan Stevanović, Juliane S. Walz
Published 2018-04-01

Designing a SARS-CoV-2 T-Cell-Inducing Vaccine for High-Risk Patient Groups

by Hans-Georg Rammensee, Cécile Gouttefangeas, Sonja Heidu, Reinhild Klein, Beate Preuß, Juliane Sarah Walz, Annika Nelde, Sebastian P. Haen, Michael Reth, Jianying Yang, Ghazaleh Tabatabai, Hans Bösmüller, Helen Hoffmann, Michael Schindler, Oliver Planz, Karl-Heinz Wiesmüller, Markus W. Löffler
Published 2021-04-01

HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy

by Annika Nelde, Juliane Sarah Walz, Daniel Johannes Kowalewski, Heiko Schuster, Olaf-Oliver Wolz, Janet Kerstin Peper, Yamel Cardona Gloria, Anton W. Langerak, Alice F. Muggen, Rainer Claus, Irina Bonzheim, Falko Fend, Helmut Rainer Salih, Lothar Kanz, Hans-Georg Rammensee, Stefan Stevanović, Alexander N. R. Weber
Published 2017-03-01

Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy

by Anna Reustle, Moreno Di Marco, Carolin Meyerhoff, Annika Nelde, Juliane S. Walz, Stefan Winter, Siahei Kandabarau, Florian Büttner, Mathias Haag, Linus Backert, Daniel J. Kowalewski, Steffen Rausch, Jörg Hennenlotter, Viktoria Stühler, Marcus Scharpf, Falko Fend, Arnulf Stenzl, Hans-Georg Rammensee, Jens Bedke, Stefan Stevanović, Matthias Schwab, Elke Schaeffeler
Published 2020-03-01

Exploring beyond clinical routine SARS-CoV-2 serology using MultiCoV-Ab to evaluate endemic coronavirus cross-reactivity

by Matthias Becker, Monika Strengert, Daniel Junker, Philipp D. Kaiser, Tobias Kerrinnes, Bjoern Traenkle, Heiko Dinter, Julia Häring, Stéphane Ghozzi, Anne Zeck, Frank Weise, Andreas Peter, Sebastian Hörber, Simon Fink, Felix Ruoff, Alex Dulovic, Tamam Bakchoul, Armin Baillot, Stefan Lohse, Markus Cornberg, Thomas Illig, Jens Gottlieb, Sigrun Smola, André Karch, Klaus Berger, Hans-Georg Rammensee, Katja Schenke-Layland, Annika Nelde, Melanie Märklin, Jonas S. Heitmann, Juliane S. Walz, Markus Templin, Thomas O. Joos, Ulrich Rothbauer, Gérard Krause, Nicole Schneiderhan-Marra
Published 2021-02-01